Search results
Showing 1051 to 1100 of 1305 results for long term conditions
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults.
Evidence-based recommendations on atezolizumab (Tecentriq) for locally advanced or metastatic non-small-cell lung cancer after chemotherapy in adults.
NICE has developed a medtech innovation briefing (MIB) on Optowire for measuring fractional flow reserve .
Evidence summaries: new medicines – Integrated process statement (PMG11)
This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs
This quality standard covers assessing and managing borderline and antisocial personality disorders. It describes high-quality care in priority areas for improvement.
View quality statements for QS88Show all sections
Sections for QS88
- Quality statements
- Quality statement 1: Structured clinical assessment
- Quality statement 2: Psychological therapies – borderline personality disorder
- Quality statement 3: Psychological therapies – antisocial personality disorder
- Quality statement 4: Pharmacological interventions
- Quality statement 5: Managing transitions
- Quality statement 6: Education and employment goals
- Quality statement 7: Staff supervision
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis
ID NG65/2 Question Long-term complications of spondyloarthritis:- What is the incidence of...
NICE has developed a medtech innovation briefing (MIB) on OxyMask for delivering oxygen therapy .
Evidence-based recommendations on CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack.
Peristeen Plus transanal irrigation system for managing bowel dysfunction (HTG462)
Evidence-based recommendations on Peristeen Plus transanal irrigation system for managing bowel dysfunction.
Thousands living with lupus offered hope from twice-yearly infusion
NICE approves breakthrough combination treatment that restores normal kidney function in almost half of patients with lupus nephritis.
NICE has developed a medtech innovation briefing (MIB) on CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease .
PleuraFlow Active Clearance Technology for maintaining chest tube patency (MIB125)
NICE has developed a medtech innovation briefing (MIB) on PleuraFlow Active Clearance Technology for maintaining chest tube patency .
This manual explains how NICE develops and updates social care guidance. It provides advice on the technical aspects of guidance development and the methods used
NICE has developed a medtech innovation briefing (MIB) on ReStore Soft Exo-Suit for gait rehabilitation .
Evidence-based recommendations on durvalumab (Imfinzi) with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults.
Show all sections
This guideline covers assessing and managing motor neurone disease (MND). It aims to improve care from the time of diagnosis, and covers information and support, organisation of care, managing symptoms and preparing for end of life care.
NICE has developed a medtech innovation briefing (MIB) on Aptiva for painful diabetic neuropathy .
This quality standard covers diagnosing and managing lung cancer in adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS17Show all sections
Sections for QS17
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway.
PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis (MIB313)
NICE has developed a medtech innovation briefing (MIB) on PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis .
people serving long-term sentences? Any explanatory notes(if applicable) Why this is important:- Case management of chronic...
NICE has developed a medtech innovation briefing (MIB) on TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation .
NICE has developed a medtech innovation briefing (MIB) on The Insides System for managing intestinal failure .
This quality standard covers treating and managing psychosis and schizophrenia in adults (aged 18 and over) in primary, secondary and community care. It also includes support for the families and carers of people with psychosis or schizophrenia. It describes high-quality care in priority areas for improvement.
View quality statements for QS80Show all sections
Sections for QS80
- Quality statements
- Quality statement 1: Referral to early intervention in psychosis services
- Quality statement 2: Cognitive behavioural therapy
- Quality statement 3: Family intervention
- Quality statement 4: Treatment with clozapine
- Quality statement 5: Supported employment programmes
- Quality statement 6: Assessing physical health
- Quality statement 7: Promoting healthy eating, physical activity and smoking cessation
This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote early detection of breast cancer (including genetic testing and mammography). It also includes advice on treatments (tamoxifen, raloxifene) and surgery (mastectomy).
Brodalumab for treating moderate to severe plaque psoriasis (TA511)
Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults.
Devices for remote monitoring of Parkinson's disease (HTG657)
Evidence-based recommendations on Kinesia 360 and KinesiaU (Great Lakes NeuroTechnologies), PDMonitor (PD Neurotechnology), Personal KinetiGraph (Global Kinetics) and STAT-ON (Sense4care) for remote monitoring of Parkinson’s disease.
The NICE public health guidance development process (third edition) (PMG5)
This manual describes how public health guidance is produced, and explains the stages of guidance development, the different activities, roles and responsibilities of different groups of people involved at different stages
Baricitinib for moderate to severe rheumatoid arthritis (TA466)
Evidence-based recommendations on baricitinib (Olumiant) for moderate to severe rheumatoid arthritis in adults.
Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema (MIB144)
NICE has developed a medtech innovation briefing (MIB) on Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema .
HemaClear for bloodless surgical field during limb surgery (MIB187)
NICE has developed a medtech innovation briefing (MIB) on HemaClear for bloodless surgical field during limb surgery .
Early value assessment (EVA) guidance on digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people.
NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts .
Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment (HTG751)
Late stage assessment (LSA) guidance on topical antimicrobial dressings for locally infected leg ulcers.
View recommendations for HTG751Show all sections
This guideline covers diagnosing and managing Lyme disease. It aims to raise awareness of when Lyme disease should be suspected and ensure that people have prompt and consistent diagnosis and treatment. It does not cover preventing Lyme disease.
Hepatitis B and C testing: people at risk of infection (PH43)
This guideline covers raising awareness of and testing for hepatitis B and C infection. It aims to ensure that people at increased risk of hepatitis B and C infection are tested.
Evidence-based recommendations on Memokath 051 Ureter stent for ureteric obstruction.
This guideline covers diagnosing and managing acute heart failure or possible acute heart failure in people aged 18 and over. It aims to improve the immediate care of someone who is acutely unwell as a result of heart failure.
Evidence-based recommendations on rimegepant (Vydura) for preventing migraine in adults.
HealthVCF for detecting vertebral compression fractures on CT scans (MIB267)
NICE has developed a medtech innovation briefing (MIB) on HealthVCF for detecting vertebral compression fractures on CT scans .
Antimicrobial prescribing: delafloxacin for community-acquired pneumonia (ES37)
Summary of the evidence on delafloxacin for community-acquired pneumonia in adults
Acoustic CR Neuromodulation for adults with chronic subjective tonal tinnitus (MIB5)
NICE has developed a Medtech Innovation Briefing (MIB) on the Acoustic CR Neuromodulation system
Early value assessment (EVA) guidance on artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals.
This guide describes the methods and processes that NICE follows when producing HealthTech guidance. For interventional procedures, this guide covers NICE processes. Methods for interventional procedures guidance are in the NICE's interventional procedures programme manual. The NICE HealthTech programme combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)
Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy.
LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis (MIB317)
NICE has developed a medtech innovation briefing (MIB) on LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis .
This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
NICE has developed a medtech innovation briefing (MIB) on Stockholm3 for prostate cancer screening .
This quality standard covers assessment, treatment, monitoring and care for children, young people and adults with an eating disorder. It describes high-quality care in priority areas for improvement.
View quality statements for QS175Show all sections
Sections for QS175
- Quality statements
- Quality statement 1: Early assessment and treatment
- Quality statement 2: Discussion about psychological treatment options
- Quality statement 3: First-line psychological treatment for binge eating disorder
- Quality statement 4: Bulimia-nervosa-focused family therapy
- Quality statement 5: Coordinated care across services
- Quality statement 6: Risk assessment when moving between services
- Update information